Concentrix (CNXC) Q1 2026 earnings review
Top-Line Growth Accelerates, But Margin Squeeze Worsens
Concentrix delivered a top-line beat in Q1 2026 with reported revenue growing 5.4% YoY to $2.50 billion (1.9% in constant currency). However, the cost of this growth was steep. Profitability took a significant step back, with Non-GAAP operating margin compressing 180 basis points YoY to 11.8%. This margin pressure flowed through to the bottom line, driving a 69% collapse in GAAP Net Income and pushing Adjusted Free Cash Flow deep into negative territory (-$144.6M). While management successfully maintained its full-year guidance and highlighted momentum in its proprietary iX Suite AI enterprise wins, the severe margin deterioration and cash consumption require immediate monitoring.
🐂 Bull Case
The Banking, Financial Services, and Insurance (BFSI) segment surged 15% YoY, and Retail, Travel & E-commerce jumped 11%, demonstrating strong execution and client vendor consolidation in key strategic verticals.
Despite a weak start to the year on cash flow and margins, management maintained its FY26 guidance for $10.035B–$10.180B in revenue and $630M–$650M in adjusted free cash flow, signaling confidence in an H2 recovery.
🐻 Bear Case
Non-GAAP operating income fell 8.2% YoY, and Adjusted EBITDA margin contracted from 15.8% to 13.9%. The company is trading margins to sustain its revenue growth and transition its portfolio.
Adjusted free cash flow usage ballooned to $144.6 million in Q1, a stark deceleration from a use of $39.8 million in the prior year, primarily driven by deteriorating operating cash flow and working capital changes.
⚖️ Verdict: 🔴
Bearish. While consecutive quarters of accelerating reported revenue growth is a positive sign, the precipitous drop in margins and severe cash burn in Q1 completely overshadow the top-line beat. Execution risk on the back half of the year has materially increased.
Key Themes
Margin Compression Reaches New Lows
Decelerating. Non-GAAP operating margin dropped significantly from 13.6% in 25Q1 to 11.8% in 26Q1. This continues a multi-quarter trend of margin degradation. Management previously attributed this to shedding low-complexity work, duplicate footprint costs, and AI investments. However, an 11.8% print is well below historical norms and implies a steep, heavily back-end loaded recovery is required to hit the ~12.5% implied FY26 guidance.
Free Cash Flow Reversing Materially
Reversing. Operating cash flow swung from a positive $1.4M in 25Q1 to a negative $83.2M in 26Q1. Adjusted free cash flow worsened to a usage of $144.6M (vs. -$39.8M in 25Q1). This creates a massive hole to climb out of to reach the reaffirmed FY26 target of $630M-$650M. The drag appears linked to changes in the outstanding factoring balance and declining net income.
BFSI and Retail Verticals Accelerating
Accelerating. The revenue growth profile was highly bifurcated. Banking, Financial Services, and Insurance (BFSI) posted an outstanding 15% YoY increase to $421.6M. Retail, Travel, and E-commerce followed suit, growing 11% YoY to $649.4M. These two segments single-handedly drove the company's top-line beat, reinforcing the narrative from prior quarters that Concentrix is successfully capturing vendor consolidation deals in these specific industries.
Healthcare and Tech Verticals Laggards
Decelerating. Conversely, Healthcare and Technology/Consumer Electronics represent significant drags on the business. Healthcare revenue fell 6% YoY, and Tech/Consumer Electronics dropped 3% YoY. The company acknowledged execution issues in Healthcare in prior quarters, and these Q1 results confirm the turnaround is not yet materializing.
iX Suite Enterprise Adoption
Stable. Management explicitly highlighted strong momentum in proprietary 'iX Suite' enterprise wins. This aligns with their long-term narrative that AI is a tailwind and differentiator, shifting the business from commodity call center work to integrated, tech-led transformation services. While the margin profile suggests these deals carry heavy near-term implementation costs, the top-line validation is evident.
Other KPIs
Decelerating. Plunged 69.3% YoY from $70.3 million. This severe GAAP contraction was driven by a $34.9M hit from acquisition/restructuring expenses, $103.5M in intangibles amortization, and a $12.3M foreign currency loss.
Stable. The company repurchased approximately 1 million shares at an average cost of $40.06 per share. While this is an increase in share volume compared to the 550,000 shares repurchased in 25Q1, the dollar amount remains disciplined relative to the $396.6M remaining authorization.
Stable. Interest expense edged up 3% YoY. The company completed an early redemption of $600 million of senior notes due August 2026, incurring $6.3M in debt extinguishment costs, which should help lower ongoing interest burdens in future quarters.
Guidance
Decelerating. The guidance implies constant currency revenue growth of 1.0% to 2.0% YoY. This is a slight step down from the 1.9% CC growth achieved in 26Q1, indicating that macro environments and deliberate portfolio shedding continue to restrict organic acceleration.
Stable. Represents a flat-to-slight deceleration from the $2.61 achieved in 26Q1, suggesting that margins will remain under significant pressure through the first half of the fiscal year.
Stable. Management maintained this full-year target despite the massive $144.6M usage in Q1. Achieving this will require a massive, accelerating inflection in working capital and operating profit generation in H2 2026.
Key Questions
Margin Trough and H2 Recovery
Non-GAAP operating margin compressed to 11.8% in Q1. Given the maintained full-year guidance, what are the specific operational milestones that give you confidence in a margin inflection in the second half of the year?
Free Cash Flow Cadence
With an adjusted free cash flow usage of $144.6 million in Q1, achieving the $630-$650 million full-year target implies generating nearly $800 million over the next three quarters. Is this strictly a reversal of temporary working capital/factoring timing, or are there underlying operational shifts required?
Healthcare and Tech Segment Weakness
Healthcare and Technology revenues declined 6% and 3% YoY respectively. Is this a structural result of your deliberate exit from low-complexity work, or are there specific macro or competitive losses occurring in these verticals?
iX Suite Margin Profile
You noted strong momentum in iX Suite enterprise wins. Can you elaborate on the margin profile of these deals during the initial implementation phase versus their steady-state run rate, and how much they contributed to Q1 margin compression?